Privia Health Group, Inc.

NasdaqGS:PRVA Stock Report

Market Cap: US$2.3b

Privia Health Group Valuation

Is PRVA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PRVA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PRVA ($19.55) is trading below our estimate of fair value ($47.07)

Significantly Below Fair Value: PRVA is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for PRVA?

Other financial metrics that can be useful for relative valuation.

PRVA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.2x
Enterprise Value/EBITDA72.9x
PEG Ratio3.8x

Price to Earnings Ratio vs Peers

How does PRVA's PE Ratio compare to its peers?

The above table shows the PE ratio for PRVA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.5x
ASTH Astrana Health
32.7x17.3%US$2.0b
AMN AMN Healthcare Services
11.1x6.7%US$2.3b
ADUS Addus HomeCare
26.6x11.7%US$1.7b
PINC Premier
15.6x7.8%US$2.6b
PRVA Privia Health Group
100.4x26.4%US$2.3b

Price-To-Earnings vs Peers: PRVA is expensive based on its Price-To-Earnings Ratio (100.4x) compared to the peer average (21.5x).


Price to Earnings Ratio vs Industry

How does PRVA's PE Ratio compare vs other companies in the US Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a12.3%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a12.3%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: PRVA is expensive based on its Price-To-Earnings Ratio (100.4x) compared to the US Healthcare industry average (24.2x).


Price to Earnings Ratio vs Fair Ratio

What is PRVA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PRVA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio100.4x
Fair PE Ratio40.9x

Price-To-Earnings vs Fair Ratio: PRVA is expensive based on its Price-To-Earnings Ratio (100.4x) compared to the estimated Fair Price-To-Earnings Ratio (40.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PRVA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$19.55
US$27.41
+40.2%
12.8%US$37.00US$21.00n/a17
Mar ’25US$22.32
US$28.56
+28.0%
16.7%US$41.00US$21.00n/a16
Feb ’25US$20.53
US$31.75
+54.7%
12.5%US$41.00US$26.00n/a16
Jan ’25US$23.03
US$32.00
+38.9%
11.6%US$41.00US$27.00n/a16
Dec ’24US$21.80
US$33.13
+51.9%
14.0%US$45.00US$27.00n/a16
Nov ’24US$20.42
US$35.84
+75.5%
16.0%US$45.00US$26.00n/a16
Oct ’24US$23.00
US$37.16
+61.5%
12.4%US$45.00US$31.50n/a16
Sep ’24US$26.29
US$37.38
+42.2%
12.2%US$45.00US$31.50n/a17
Aug ’24US$27.70
US$38.29
+38.2%
11.6%US$45.00US$30.00n/a17
Jul ’24US$26.11
US$38.41
+47.1%
11.2%US$45.00US$30.00n/a17
Jun ’24US$24.37
US$38.69
+58.8%
11.1%US$45.00US$30.00n/a16
May ’24US$27.98
US$38.38
+37.2%
12.7%US$45.00US$30.00n/a16
Apr ’24US$27.61
US$38.80
+40.5%
12.4%US$45.00US$30.00n/a15
Mar ’24US$28.24
US$39.21
+38.9%
13.2%US$45.00US$30.00US$22.3214
Feb ’24US$27.61
US$39.31
+42.4%
13.6%US$45.00US$30.00US$20.5313
Jan ’24US$22.71
US$40.46
+78.2%
13.0%US$45.00US$28.00US$23.0313
Dec ’23US$24.17
US$42.55
+76.0%
4.7%US$45.00US$39.00US$21.8011
Nov ’23US$32.69
US$46.64
+42.7%
8.2%US$54.00US$41.00US$20.4211
Oct ’23US$34.06
US$46.64
+36.9%
8.2%US$54.00US$41.00US$23.0011
Sep ’23US$39.70
US$45.64
+15.0%
6.2%US$51.00US$41.00US$26.2911
Aug ’23US$36.82
US$36.91
+0.2%
8.2%US$41.00US$33.00US$27.7011
Jul ’23US$28.90
US$35.36
+22.4%
7.3%US$40.00US$32.00US$26.1111
Jun ’23US$22.96
US$33.91
+47.7%
10.0%US$40.00US$27.00US$24.3711
May ’23US$21.99
US$38.60
+75.5%
11.7%US$45.00US$33.00US$27.9810
Apr ’23US$27.41
US$39.00
+42.3%
11.7%US$45.00US$33.00US$27.619
Mar ’23US$25.52
US$42.38
+66.0%
15.6%US$51.00US$33.00US$28.248

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.